Evidence map›Paper›PMID 29785539›Full record

ArticleCardiology and therapy2018

The Effect of Spironolactone on the Incidence of Contrast-Induced Nephropathy in Patients Undergoing Cardiac Catheterization: Study Design and Rationale.

Alhasan Mujtaba, Mohammed A Taher, Mazin A Hazza, Hassan M Al-Rubaye, Asaad H Kata, Hamid AbdulWahab, AbdulAmeer AbdulBari, Hayder K AlRubay

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiology and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03329443 (The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03329443 phase2completednot on this map

The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography

TypeinterventionalSponsorAlhasan Mujtaba Abdul-WahidRan2017 to 2018Enrolled490ConditionsAcute Kidney Injury, IHD, Contrast-induced NephropathyArmsSpironolactone, Placebo Oral Tablet
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Diuretics for preventing and treating acute kidney injury.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Alhasan MujtabaDepartment of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Basra, Iraq. user11126@gmail.com.ORCID http://orcid.org/0000-0003-0819-1780
Mohammed A TaherDepartment of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Basra, Iraq.
Mazin A HazzaCollege of Medicine, University of Basra, Basra, Iraq.
Hassan M Al-RubayeBasra Cardiac Catheterization Center, Basra, Iraq.
Asaad H KataBasra Cardiac Catheterization Center, Basra, Iraq.
Hamid AbdulWahabBasra Cardiac Catheterization Center, Basra, Iraq.
AbdulAmeer AbdulBariCollege of Medicine, University of Basra, Basra, Iraq.
Hayder K AlRubayAlSader Teaching Hospital, Basra, Iraq.
University of Basrah · IQAlsalam University College · IQUniversity of Baghdad · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients undergoing coronary catheterization are at high risk of developing contrast-induced nephropathy (CIN) acute kidney injury (AKI). Several approaches have been supposed to limit such an effect but with mixed results or non-practical methods. Spironolactone is supposed to be effective as a nephroprotective agent in animal studies. This study will try to measure the effect of spironolactone on the incidence of CIN-AKI in patients undergoing coronary catheterization (angiography angioplasty).

methodsThis study is a single-center, investigator-driven, double-blinded randomized controlled study in Iraq-Basra. More than 400 patients admitted for coronary angio unit in our center will be allocated in a 1:1 ratio to receive either spironolactone 200 mg single dose or placebo in addition to their usual premedication. PLANNED OUTCOMES: Primary end point will be CIN defined as more than 25% or 0.3 mg/dl elevation in serum creatinine (S.Cr.) from baseline during the first 2-3 days after the procedure. We hope to identify or answer an important question regarding CIN in such high-risk patients.

trial registrationClinicalTrials.gov Identifier, NCT03329443.

Indexed as

Acute kidney injury (AKI)AldactoneAngiographyAngioplastyContrast-induced nephropathy (CIN)Ischemic heart disease (IHD)Percutaneous coronary angiography (PCI)Spironolactone

Identifiers

PMID29785539
PMCPMC5986677
OpenAlexW2804130924

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.